Loading patent…
AssigneeMaxygen, Inc.
InventorsJuha Punnonen, Alexandra L.L. Lazetic, Steven R. Leong, Chia-Chun Jean Chang, Doris Apt, Claes Gustafsson
Estimating the term…
The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
An isolated or recombinant polypeptide comprising an extracellular domain sequence, wherein said extracellular domain sequence has at least about 75% amino acid sequence identity to an extracellular domain sequence of at least one of SEQ ID NOS:
An isolated or recombinant polypeptide, which polypeptide comprises a non-naturally-occurring amino acid sequence encoded by a nucleic acid comprising a polynucleotide sequence selected from the group of:
An isolated or recombinant polypeptide comprising a sequence according to the formula:
An isolated or recombinant polypeptide comprising a subsequence of an amino acid sequence set forth in any of SEQ ID NOS:
A composition comprising:
An isolated or recombinant nucleic acid comprising a polynucleotide sequence selected from:
An isolated or recombinant nucleic acid comprising a polynucleotide sequence encoding a polypeptide, wherein the encoded polypeptide comprises an amino acid sequence which is (a) substantially identical over at least about 150 contiguous amino acid residues of any one of SEQ ID NOS:
An isolated or recombinant nucleic acid comprising a nucleotide sequence coding for a polypeptide comprising the amino acid sequence set forth in any of SEQ ID NOS:
An isolated or recombinant polypeptide comprising a sequence having at least about 95% identity to at least about one of SEQ ID NOS:
An isolated or recombinant polypeptide comprising a sequence that differs from a primate B7-1 sequence in at least one mutation selected from:
An isolated or recombinant polypeptide comprising a sequence, said sequence having at least about 75% identity to at least one of SEQ ID NOS:
An isolated or recombinant polypeptide, which polypeptide comprises a non naturally-occurring amino acid sequence encoded by a nucleic acid comprising a polynucleotide sequence selected from:
An isolated or recombinant polypeptide comprising a sequence according to the formula:
An isolated or recombinant polypeptide comprising a subsequence of an amino acid sequence set forth in any of SEQ ID NOS:
A composition comprising:
An isolated or recombinant nucleic acid comprising a polynucleotide sequence selected from:
An isolated or recombinant nucleic acid comprising a polynucleotide sequence selected from:
An isolated or recombinant nucleic acid comprising a polynucleotide sequence encoding a polypeptide, the encoded polypeptide comprising an amino acid sequence which is substantially identical over at least about 150 contiguous amino acid residues of any one of SEQ ID NOS:
An isolated or recombinant nucleic acid comprising a nucleotide sequence coding for a polypeptide comprising the amino acid sequence set forth in any of SEQ ID NOS:
An isolated or recombinant polypeptide comprising a sequence according to the formula:
An isolated or recombinant polypeptide comprising a sequence according to the formula:
An isolated or recombinant polypeptide comprising the sequence SEQ ID NO:
An isolated or recombinant nucleic acid comprising a polynucleotide sequence selected from:
A polypeptide which is specifically bound by a polyclonal antisera raised against one or more antigen, the antigen comprising the sequence SEQ ID NOS:
An antibody or antisera which specifically binds a polypeptide, the polypeptide comprising a sequence selected from:
A computer or computer readable medium comprising a database comprising a sequence record comprising one or more character string corresponding to a nucleic acid or protein sequence selected from SEQ ID NOS:
An integrated system comprising a computer or computer readable medium comprising a database comprising one or more sequence records, each comprising one or more character strings corresponding to a nucleic acid or protein sequence selected from SEQ ID NOS:
A method of using a computer system to present information pertaining to at least one of a plurality of sequence records stored in a database, said sequence records each comprising one or more character string corresponding to SEQ ID NOS:
A nucleic acid which comprises a unique subsequence in a nucleic acid selected from SEQ ID NOS:
A polypeptide which comprises a unique subsequence in a polypeptide selected from:
A target nucleic acid which hybridizes under stringent conditions to a unique coding oligonucleotide which encodes a unique subsequence in a polypeptide selected from:
A method of modulating or altering a T-cell response specific to an antigen in a subject, the method comprising administering to the subject at least one polynucleotide sequence encoding a polypeptide comprising any of SEQ ID NOS:
A vector comprising at least one polynucleotide sequence encoding a polypeptide comprising any of SEQ ID NOS:
A vector comprising at least one polynucleotide sequence encoding a polypeptide comprising any of SEQ ID NOS:
A method of modulating or altering an immune response in a subject, the method comprising introducing into cells of a tumor of the subject at least one polynucleotide sequence encoding a polypeptide comprising any of SEQ ID NOS:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Term end not estimated
Receptors; Cell surface antigens; Cell surface determinants: immunoglobulin superfamily
Medicinal preparations containing peptides
Peptides
Medicines and medical preparations
Backward citations are indexed for grants only.
Pursuant to 37 C.F.R. 1.71(e), Applicants note that a portion of this disclosure contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.
The present invention relates generally to polynucleotides and polypeptides encoded therefrom, as wells as vectors, cells, antibodies, and methods for using and producing the polynucleotides and polypeptides.
T cells are a crucial component of the immune system. Not only is T cell activation required for all specific immune responses against infectious agents, but T cells also play an important role in tumor immunity and in autoimmune and allergic diseases. T cell activation is initiated when T cells recognize their specific antigen (Ag) in the context of major histocompatibility complex (MHC) molecules. T cell activation is well known by those of ordinary skill in the art and is characterized by such things as, e.g., cytokine synthesis, induction of various activation markers such as CD25 (interleukin-2 (IL-2) receptor), etc. CD4+T cells recognize their immunogenic peptides in the context of MHC class II molecules, whereas CD8+T cells recognize their immunogenic peptides in the context of MHC class I molecules. For induction of T cell activation, cytokine synthesis or effector function, a second signal, mediated through CD28, is required. Two ligands for CD28 are B7-1 (CD80) and B7-2 (CD86). B7-1 and B7-2 are termed co-stimulatory molecules and are typically expressed on professional antigen-presenting cells (APCs). In addition to binding the CD28 receptor, B7-1 and B7-2 also bind the CTLA-4 (CD152) receptor on T cells.
FIG. 1A is a schematic representation of exemplary interactions between 1) a T cell receptor (TCR) and antigenic peptide presented in the groove of a major histocompatibility complex (MHC) molecule, and 2) a recombinant CD28BP polypeptide of the invention expressed on the surface of an antigen-presenting cell (APC) and a CD28 receptor on a T cell. FIG. 1B is a schematic representation of exemplary interactions between 1) a TCR and antigenic peptide presented in the groove of a MHC molecule, and 2) a recombinant CTL4-BP polypeptide of the invention expressed on the surface of an APC and a CTLA-4 receptor on a T cell. The representation illustrates the principle by which recombinant polypeptides of the invention which preferentially bind the CD28 or CTLA-4 receptor effectuating enhanced or suppressed T cell activation.
FIGS. 2A-2H depict an alignment of a naturally-occurring (i.e., wild-type) human B7-1 polypeptide sequence (SEQ ID NO: 278) and exemplary CD28BP polypeptide sequences of the invention (SEQ ID NOS: 48-68, SEQ ID NOS: 174-221, and SEQ ID NO: 283). The predicted boundaries between the signal peptide region, extracellular domain (ECD), transmembrane domain (TMD), and cytoplasmic domain (CD), based on corresponding boundaries in the hB7-1 sequence are shown at the top. The arrow positioned between the amino acid residues equivalent to amino acid residues 34-35 of SEQ ID NO: 278, indicates the predicted boundary between the signal peptide region and the mature polypeptide region based on comparison with the hB7-1 sequence. SEQ ID NO: 283 represents a “consensus sequence” of these aligned CD28BP sequences.
FIGS. 3A-3H illustrate an alignment of a naturally-occurring (i.e., wild-type) hB7-1 polypeptide sequence (SEQ ID NO: 278 ) and exemplary CTLA-4BP polypeptide sequences of the invention (SEQ ID NOS: 69-73, SEQ ID NOS: 74-92, SEQ ID NO: 222-252, and SEQ ID NO: 286). The predicted boundaries between the signal peptide sequence, ECD, TMD, and CD, based on corresponding boundaries in the hB7-1 sequence are shown at the top. SEQ ID NO: 286 represents a “consensus sequence” of these aligned CTLA-4BP sequences of the invention. Alignments shown in FIGS. 2A-2H and 3A-3H were prepared using the CLUSTALW multiple sequence alignment program, a part of the Vector NTI version 6 sequence analysis software package (Informax, Bethesda, Md.). CLUSTALW initially performs multiple pairwise comparisons between groups of sequences and then assembles the pairwise alignments into a multiple alignment based on homology. For the initial pairwise alignments, Gap Open and Gap Extension penalties were 10 and 0.1, respectively. For the multiple alignments, Gap Open penalty was 10, and the Gap Extension penalty was 0.05. The BLOSUM62 matrix was the protein weight matrix.
The expression of B7-1 has been shown to be an important mechanism of immune responses in mammals, including humans. It is believed that at least two signals are required for activation of T cells by antigen-bearing target cells: 1) an antigen-specific signal, delivered through the T cell receptor (TCR); and 2) an antigen-independent or co-stimulatory signal that leads to the production of lymphokine products (Hodge et al. (1994) Cancer Res. 54:5552-5555). B7-1, which is typically expressed on antigen-presenting cells (APC), has been determined to be a ligand for two T cell surface antigen receptors: CD28 and CTLA-4. Both receptors are present on T cells, although they are expressed at different times and in different amounts. T cell activation is a prerequisite for all specific immune responses. However, if only one T cell activation signal is received by a T cell, activation will likely not occur, and anergy may result. For example, many tumor cells do not express B7-1. Consequently, even when a tumor expresses a potential rejection antigen, it is not likely that it will be able to activate an antitumor T cell response. Id. For T cell activation and enhanced immune response, an additional antigen-independent signal, such as from B7-1, is believed necessary.
The human CD28 receptor and human CTLA-4 receptor are naturally activated in human cells by B7-1. In some studies, the reported binding affinities of CTLA-4 and CD28 to WT hB7-1 were found to be about 0.2-0.4×10−6 M and about 4×10−6 M, respectively (van der Merwe et al. (1997) J. Exp. Med. 185:393; Ikemizu et al. (2000) Immunity 12:51). However, different studies have reported different binding affinities.
The amino acid sequence of full-length WT hB7-1 comprises 288 amino acids (GenBank Protein Access. No. P33681). The signal peptide (which is cleaved in the secreted form) comprises amino acid residues 1-34, the extracellular domain (ECD) comprises amino acid residues 35-242, the transmembrane domain comprises amino acid residues 243-263, and the cytoplasmic domain comprises amino acid residues 264-288. The mature form of hB7-1, which has a total of 254 amino acids, comprises amino acid residues 35-288 (the full-length sequence without the signal peptide), and begins with the amino acid sequence: valine-isoleucine-histidine-valine. If desired, the amino acids of the mature form can be numbered beginning with the Val of the Val-Ile-His-Val sequence, designating Val as the first residue (e.g., amino acid residues number 1-208). In another aspect, the ECD of hB7-1 comprises amino acid residues 1-208, the transmembrane domain comprises amino acid residues 209-235, and the cytoplasmic domain comprises amino acid residues 236-254 of the full-length mature hB7-1 sequence when numbered beginning with the Val of the Val-Ile-His-Val sequence as described above. See, e.g., U.S. Pat. No. 6,071,716. There are eight possible glycosylation sites (Asn-X-Ser/Thr) in hB7-1 ECD. The transmembrane domain includes at least 3 cysteine residues that may be involved in binding to other polypeptides or lipid derivatization. Id.